When semaglutide was approved to treat Type 2 diabestes in 2017, Novo named it Ozempic
Support from healthcare teams, including dietitians and diabetes educators, can provide valuable guidance and motivation, ensuring that patients are equipped with the tools they need to succeed on their treatment journey

Before starting or continuing both medications together, ensure you discuss: Your Complete Medical History: Previous or current mental health conditions, including depression, anxiety, bipolar disorder, or suicidal ideation History of seizures or conditions that lower seizure threshold Eating disorders (past or present) Cardiovascular disease, including hypertension Kidney or liver impairment Thyroid disorders Diabetes and current glycaemic control Gastrointestinal conditions, including pancreatitis or gallbladder disease Eligibility for Wegovy under NICE guidelines (typically requiring specialist weight management services, specific BMI thresholds, and other criteria) All Current Medications: Provide a complete list including: Prescription medications (especially anticoagulants like warfarin, antidiabetic drugs, or medications affecting seizure threshold such as tramadol, antipsychotics, tricyclic antidepressants, or quinolone antibiotics) Medications that affect CYP2B6 enzymes which metabolise bupropion Over-the-counter medicines Herbal supplements and vitamins Recreational substances or alcohol use Treatment Goals and Monitoring: Discuss realistic expectations for weight management and smoking cessation

The effect of liraglutide on endothelial function in patients with type 2 diabetes
Important: IGF-1 LR3 is not FDA-approved for any indication